bpc 157 wolverine protocol (BPC-157/TB-500) — IVs in the Keys bpc-157 tb-500 wolverine protocol The

Background BPC-157 was initially synthesized in the early 1990s and studied for its cytoprotective properties as an anti-ulcer agent

An active member in the local community, Maureen has served as board member and co-chair of the Mentor Protg Committee for Women in Technology, is a member of the Executive Womens Board of the City Club of Washington, and is a member of the Board of Governors of the Capital Society

What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects

No, clinical trials definitively demonstrated that AOD-9604 has no effect on serum IGF-1 levels